Skip to Content

CCIR-initiated Clinical Trials

CCIR members take advantage of resources offered by MD Anderson, including the CCSG Shared Resources, Immune Monitoring Core Laboratory and GMP Cell Facility, allowing them to follow the “bench-to-beside-and-back-again” approach to develop and improve cancer immunotherapy in the form of cellular therapy, a vaccine or targeting antibody, either alone or in combination with conventional therapies or newly developed therapies. CCIR members are testing the utility of immune checkpoint blockade in lymphoma (shown by Dr. Allison to be effective against melanoma), genetic engineering in cell therapy (e.g., CD19, CXCR2, TGF-β DNR), and TLR agonists or IL-2 in vaccine formulations as well as some novel combination therapies, such as the infusion of tumor-reactive lymphocytes from HLA-matched donors  who were vaccinated with a lymphoma idiotype.

Chart illustrating progress of CCIR cancer immunotherapies as they advance to each phase of a clinical trial toward FDA approval

Links to Information about Clinical Trials 

Infusion of CAR T cells: Patients with advanced B cell-lineage lymphoid malignancies (NCT00968760)

Infusion of haploidentical natural killer (NK) cells: Patients with relapsed neuroblastoma (NCT00698009)

Infusion of haploidentical NK cells combined with epratuzumab (CD22-specific monoclonal antibody):  Patients with relapsed acute lymphoblastic leukemia (NCT00941928)

TLR agonist plus vaccination with  the melanoma-associated peptides gp100 and MAGE-3:  Patients with metastatic melanoma with measurable disease, stage IIIC (in transient lesions) or stage IV M1A with disease that includes lesions accessible for biopsies (NCT00960752)

Adoptive T cell transfer plus dendritic cell vaccination: Patients with advanced stage of melanoma (NCT00338377)

Leuprolide plus vaccination with the melanoma-associated peptides gp100 and MAGE-3:  Patients with stage IIb-IV melanoma (NCT00254397)

PR1 (leukemia-associated peptide) Vaccine: Patients with chronic myeloid leukemia, acute myeloid leukemia or myelodysplastic syndromes (NCT00004918)

Gp100 (melanoma-associated peptide) Vaccine: Patients with Stage IIb-III or stage IV melanoma (NCT00019682)

Lymphoma Idiotype Vaccine: Patients with follicular B cell Non-Hodgkin's lymphoma (NCT00089115), indolent B cell Non-Hodgkin's lymphoma (NCT00258336) or mantle cell lymphoma (NCT00020215)

Lymphoma Idiotype Vaccine plus GM-CSF: Follicular lymphoma patients undergoing first complete remission (NCT00091676)

Related Diseases

More Information and How to Donate


© 2013 The University of Texas MD Anderson Cancer Center